DM1 is a rare muscular disorder that leads to muscle weakness, myotonia, and mobility issues. DYNE-101 and AOC-1001 are the most advanced assets in clinical development. In pivotal trials, I expect DYNE-101 and AOC-1001 to show statistically significant and similar efficacy results, but AOC-1001 may carry higher safety risk than DYNE-101.